Lucile Brun1, Romain Lefaucheur1, Damien Fetter1, Stéphane Derrey2, Alaina Borden1, David Wallon1, Bertrand Bourre1, David Maltête3. 1. Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France. 2. Department of Neurosurgery, Rouen University Hospital and University of Rouen, Rouen, France. 3. Department of Neurology, Rouen University Hospital and University of Rouen, Rouen, France; INSERM U1079, Rouen Faculty of Medicine, Rouen, France. Electronic address: david.maltete@chu-rouen.fr.
Abstract
OBJECTIVE: To describe demographic and clinical characteristics in a group of Parkinson's disease (PD) patients with non-motor fluctuations (NMF) and to evaluate the management of medications proposed to treat NMF. METHODS: Three hundred and three PD patients (mean age, 66 ± 10.3 years; mean disease duration, 10.1 ± 6.5 years) were enrolled. Each patient was interviewed in a non-directed fashion about the main NMF manifestations, i.e. dysautonomic, mental, and sensory symptoms. Both groups of patients with and without NMF were compared. Dysautonomia, motor fluctuations, age, disease duration, and LEDD were included in a multiple regression to determine which were predictive of NMF. RESULTS: NMF were found in 57 (19%) patients, mean age 65 ± 10.1 years, mean age at onset of PD 53.7 ± 10.9 years, mean disease duration 12.5 ± 6.9 years. NMF occurred on average 9.8 ± 7.7 years after the onset of PD. Fifty patients (86%) with NMF had also MF and 10 (21%) had PDD. Twenty-five (44%) patients suffered from sensory, 28 (49%) from autonomic and 25 (44%) from neuropsychiatric symptoms. Both disease and L-Dopa treatment durations, and LEDD were significantly higher in NMF patient's group. Motor fluctuations (p = 0.0016) and presence of dysautonomia (p = 0.007) were found to be two independent predictors of NMF. CONCLUSION: The development of new instruments to assess NMF is crucial for optimized management of advanced PD.
OBJECTIVE: To describe demographic and clinical characteristics in a group of Parkinson's disease (PD) patients with non-motor fluctuations (NMF) and to evaluate the management of medications proposed to treat NMF. METHODS: Three hundred and three PDpatients (mean age, 66 ± 10.3 years; mean disease duration, 10.1 ± 6.5 years) were enrolled. Each patient was interviewed in a non-directed fashion about the main NMF manifestations, i.e. dysautonomic, mental, and sensory symptoms. Both groups of patients with and without NMF were compared. Dysautonomia, motor fluctuations, age, disease duration, and LEDD were included in a multiple regression to determine which were predictive of NMF. RESULTS: NMF were found in 57 (19%) patients, mean age 65 ± 10.1 years, mean age at onset of PD 53.7 ± 10.9 years, mean disease duration 12.5 ± 6.9 years. NMF occurred on average 9.8 ± 7.7 years after the onset of PD. Fifty patients (86%) with NMF had also MF and 10 (21%) had PDD. Twenty-five (44%) patients suffered from sensory, 28 (49%) from autonomic and 25 (44%) from neuropsychiatric symptoms. Both disease and L-Dopa treatment durations, and LEDD were significantly higher in NMF patient's group. Motor fluctuations (p = 0.0016) and presence of dysautonomia (p = 0.007) were found to be two independent predictors of NMF. CONCLUSION: The development of new instruments to assess NMF is crucial for optimized management of advanced PD.
Authors: Joseph Classen; Jiri Koschel; Christian Oehlwein; Klaus Seppi; Peter Urban; Christian Winkler; Ullrich Wüllner; Alexander Storch Journal: J Neural Transm (Vienna) Date: 2017-07-12 Impact factor: 3.575
Authors: Elena Makovac; Mara Cercignani; Laura Serra; Mario Torso; Barbara Spanò; Simona Petrucci; Lucia Ricciardi; Monia Ginevrino; Carlo Caltagirone; Anna Rita Bentivoglio; Enza Maria Valente; Marco Bozzali Journal: PLoS One Date: 2016-10-27 Impact factor: 3.240
Authors: Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub Journal: Mov Disord Clin Pract Date: 2020-12-21
Authors: József Attila Szász; Viorelia Adelina Constantin; Károly Orbán-Kis; Attila Rácz; Ligia Ariana Bancu; Dan Georgescu; János Szederjesi; István Mihály; Ana-Mária Fárr; Krisztina Kelemen; Tamás Vajda; Szabolcs Szatmári Journal: Neuropsychiatr Dis Treat Date: 2019-11-13 Impact factor: 2.570
Authors: Alberto J Espay; Paolo Bonato; Fatta B Nahab; Walter Maetzler; John M Dean; Jochen Klucken; Bjoern M Eskofier; Aristide Merola; Fay Horak; Anthony E Lang; Ralf Reilmann; Joe Giuffrida; Alice Nieuwboer; Malcolm Horne; Max A Little; Irene Litvan; Tanya Simuni; E Ray Dorsey; Michelle A Burack; Ken Kubota; Anita Kamondi; Catarina Godinho; Jean-Francois Daneault; Georgia Mitsi; Lothar Krinke; Jeffery M Hausdorff; Bastiaan R Bloem; Spyros Papapetropoulos Journal: Mov Disord Date: 2016-04-29 Impact factor: 10.338